Multivariate analyses of the impact of allele-level HLA typing on transplant outcomes other than overall survival
| Transplant predictors . | Multivariate HRs (95% CI) and P values . | |||||
|---|---|---|---|---|---|---|
| Neutrophil recovery . | Day-100 TRM . | TRM . | Relapse/progression . | Grade 2-4 aGHVD . | cGHVD . | |
| 3 vs 0-2 MM∗ | 0.76 (0.58-0.99); P = .04 | 1.44 (0.83-2.48); P = .19 | 1.09 (0.63-1.91); P = .76 | 0.79 (0.53-1.20); P = .27 | 0.99 (0.71-1.38); P = .94 | 0.90 (0.60-1.36); P = .62 |
| 4 vs 0-2 MM∗ | 0.74 (0.57-0.96); P = .03 | 1.80 (1.06-3.05); P = .03 | 1.36 (0.80-2.32); P = .26 | 0.81 (0.54-1.21); P = .31 | 0.91 (0.66-1.27); P = .60 | 0.84 (0.55-1.26); P = .39 |
| ≥5 vs 0-2 MM∗ | 0.84 (0.64-1.10); P = .20 | 2.32 (1.38-3.91); P = .002 | 2.12 (1.25-3.61); P = .005 | 0.58 (0.37-0.89); P = .01 | 1.17 (0.84-1.64); P = .35 | 0.97 (0.64-1.47); P = .89 |
| ≥4 vs 0-3 MM† | 0.94 (0.80-1.11); P = .46 | 1.54 (1.18-2.03); P = .002 | 1.58 (1.18-2.11); P = .002 | 0.83 (0.64-1.07); P = .14 | 1.03 (0.85-1.26); P = .75 | 0.96 (0.75-1.23); P = .76 |
| Transplant predictors . | Multivariate HRs (95% CI) and P values . | |||||
|---|---|---|---|---|---|---|
| Neutrophil recovery . | Day-100 TRM . | TRM . | Relapse/progression . | Grade 2-4 aGHVD . | cGHVD . | |
| 3 vs 0-2 MM∗ | 0.76 (0.58-0.99); P = .04 | 1.44 (0.83-2.48); P = .19 | 1.09 (0.63-1.91); P = .76 | 0.79 (0.53-1.20); P = .27 | 0.99 (0.71-1.38); P = .94 | 0.90 (0.60-1.36); P = .62 |
| 4 vs 0-2 MM∗ | 0.74 (0.57-0.96); P = .03 | 1.80 (1.06-3.05); P = .03 | 1.36 (0.80-2.32); P = .26 | 0.81 (0.54-1.21); P = .31 | 0.91 (0.66-1.27); P = .60 | 0.84 (0.55-1.26); P = .39 |
| ≥5 vs 0-2 MM∗ | 0.84 (0.64-1.10); P = .20 | 2.32 (1.38-3.91); P = .002 | 2.12 (1.25-3.61); P = .005 | 0.58 (0.37-0.89); P = .01 | 1.17 (0.84-1.64); P = .35 | 0.97 (0.64-1.47); P = .89 |
| ≥4 vs 0-3 MM† | 0.94 (0.80-1.11); P = .46 | 1.54 (1.18-2.03); P = .002 | 1.58 (1.18-2.11); P = .002 | 0.83 (0.64-1.07); P = .14 | 1.03 (0.85-1.26); P = .75 | 0.96 (0.75-1.23); P = .76 |
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease.
Other predictor variables according to outcomes: Neutrophil recovery (N = 703): TNC > 3.5 × 107/kg (HR, 1.47; P = .04); CD34 cell count > 1.4 × 105/kg (HR, 1.33; P = .006), plasma cell disorder (HR, 1.81; P = .002) and myeloproliferative disorder (HR, 0.49; P = <.001). Day-100 TRM (n = 781): > 45 years (HR, 1.42; P = .01), weight > 87 kg (HR, 1.70; P < .001), myeloproliferative disorder (HR, 2.18; P < .001), myelodysplastic syndrome (HR, 1.55; P = .04) and TNC >3.5 (HR, 0.61; P = .02).TRM (n = 688): myeloproliferative disorder (HR, 2.06; P = .001), myelodysplastic syndrome (HR, 1.64; P = .03), lymphoproliferative disorder (HR, 1.45; P = .03) and ATG use (HR, 1.40; P = .03). Relapse/progression (n = 909): High-dose TBI (≥8 Gy) vs no TBI (HR, 0.50; P = .003), myelodysplastic syndrome (HR, 0.39; P = .005), lymphoproliferative disorder (HR, 0.66; P = .02) and transplants performed after 2011 (HR, 0.61; P < .001). aGVHD: No adjustment in the model (n = 948). cGVHD (n = 791): High-dose TBI (≥8 Gy) vs no TBI (HR, 1.91; P = .003) and UCB–recipient sex mismatch (HR, 0.75; P < .03).
Other predictor variables according to outcomes: Neutrophil recovery (n = 704): CD34 cell count > 1.4 × 105/kg (HR, 1.44; P = < .001) plasma cell disorder (HR, 1.75; P = .003), myeloproliferative disorder (HR, 0.49; P <.001) and myelodysplastic syndrome (HR, 0.73; P = .03). Day-100 TNC (n = 781): > 45 years (HR, 1.39; P = .02), weight > 87 kg (HR, 1.71; P < .001), myeloproliferative disorder (HR, 2.17; P < .001) and TNC > 3.5 × 107/kg (HR, 0.61; P = .03). TRM (n = 688): Myeloproliferative disorder (HR, 2.04; P = .002), lymphoproliferative disorder (HR, 1.44; P = .03) and ATG use (HR, 1.39; P = .03). Relapse/progression (n = 909): High-dose TBI (≥8 Gy) vs no TBI (HR, 0.54; P = .006) transplants after 2011 (HR, 0.59; P < .001). aGVHD: No adjustment in the model (n = 948). cGVHD (n = 791): High-dose TBI (≥8 Gy) vs no TBI (HR, 1.91; P = .003) and UCB–recipient sex mismatch (HR, 0.75; P < .03).